What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 147″]

Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashley McEvoy , Company Group Chairman for Johnson & Johnson Vision, explains where TearScience will fit into J&J if the deal is completed and what the global giant’s plans for additional Dry Eye treatments may be.

Want to know more about this podcast guest?

Ashley McEvoy: https://ois.net/ashley-mcevoy/